| Philips to acquire Northern Ireland based healthcare IT company TOMCAT Systems, dated March 26, 2008; | |
| Philips to establish a manufacturing joint venture for energy-saving light bulbs in Southern Africa, dated March 27, 2008; | |
| Philips notifies Dutch Authority for the Financial Markets of holding over 5% of its own shares, dated March 31, 2008; | |
| Philips takes decisive steps to improve profitability of its television business, dated April 8, 2008; | |
| Philips to acquire Chinese patient monitoring company Shenzhen Goldway Industrial, Inc., dated April 11, 2008. |
KONINKLIJKE PHILIPS ELECTRONICS
N.V. |
||||
/s/ E.P. Coutinho | ||||
(General Secretary) | ||||
| Group sales increase to EUR 5,965 million; growth in Healthcare and Lighting offset by lower television sales. |
| Ongoing growth at Healthcare with 5% higher sales; 9% higher equipment order intake, including double-digit growth in North America. |
| Continuing strong growth of 17% in emerging markets. |
| Decisive action taken to improve the profitability of the television business through an alliance with Funai in North America and optimization of the global supply base. |
| Net income of EUR 219 million, compared with EUR 875 million in Q1 2007, when EUR 650 million higher gains on the sale of stakes boosted the bottom line. |
| Vision 2010 EBITA target specified and upgraded to 10-11%. |
2
3
Q1 | Q1 | |||||||
2007 | 2008 | |||||||
Sales |
5,930 | 5,965 | ||||||
EBITA |
370 | 265 | ||||||
as a % of sales |
6.2 | 4.4 | ||||||
EBIT |
312 | 175 | ||||||
as a % of sales |
5.3 | 2.9 | ||||||
Financial income and expenses |
681 | 46 | ||||||
Income tax expense |
(92 | ) | (49 | ) | ||||
Results equity-accounted investees |
(49 | ) | 60 | |||||
Income from continuing operations |
852 | 232 | ||||||
Discontinued operations |
23 | (13 | ) | |||||
Net income |
875 | 219 | ||||||
Per common share (in euros) basic |
0.80 | 0.21 |
% change | ||||||||||||||||
Q1 | Q1 | compa- | ||||||||||||||
2007 | 2008 | nominal | rable | |||||||||||||
Healthcare |
1,431 | 1,474 | 3 | 5 | ||||||||||||
Lighting |
1,474 | 1,711 | 16 | 3 | ||||||||||||
Consumer Lifestyle |
2,816 | 2,662 | (5 | ) | | |||||||||||
I&EB |
160 | 79 | (51 | ) | (22 | ) | ||||||||||
GM&S |
49 | 39 | (20 | ) | (22 | ) | ||||||||||
Philips Group |
5,930 | 5,965 | 1 | 1 |
| The decline in income from continuing operations compared to Q1 2007 was attributable to lower year-on-year gains on the sale of stakes. Q1 2007 included a net gain of EUR 733 million from the partial sale of our shareholding in TSMC, whereas Q1 2008 included a EUR 83 million gain on the partial sale of the shareholding in LG Display. The revaluation result recorded on the options related to the TPV convertible bonds was EUR 21 million lower than in Q1 2007. |
| EBITA was EUR 105 million lower than in Q1 2007, entirely due to a EUR 44 million reduction in earnings at Connected Displays, EUR 38 million of acquisition-related charges in Healthcare and Lighting, and a EUR 52 million reduction in license income, mainly incidental past-use optical license revenues. |
| Results relating to equity-accounted investees increased by EUR 109 million year-on-year, entirely driven by improved operational results at LG Display. |
| The lower income from discontinued operations was attributable to final settlements in Q1 2007 relating to the Semiconductors transaction. |
| Sales in the quarter totaled EUR 5,965 million, a nominal increase of 1% compared to Q1 2007. Excluding portfolio changes (4%) and a negative currency impact, comparable sales also grew by 1%, driven by Healthcare and Lighting. Comparable sales at Consumer Lifestyle were flat year-on-year. |
| Healthcare sales grew 5% on a comparable basis, mainly driven by growth in Ultrasound, Cardiac Care, Customer Services and Patient Monitoring. Comparable sales at Imaging Systems were at the same level as in Q1 2007. |
| Lighting sales showed comparable growth of 3%, driven by growth in Lamps, Lighting Electronics and Professional Luminaires, partly offset by lower sales at Special Lighting Applications and at Lumileds due to a product recall earlier in the quarter. |
| Consumer Lifestyle sales were on par with Q1 2007 on a comparable basis. Solid growth was seen in Domestic Appliances, Shaving & Beauty and Home Networks, offset by lower sales at Connected Displays (mainly consumer television) and Video & Multimedia Applications. |
| Sales in I&EB decreased 22% on a comparable basis, mainly due to a decline in license revenues. |
4
% change | ||||||||||||||||
Q1 | Q1 | compa- | ||||||||||||||
2007 | 2008 | nominal | rable | |||||||||||||
Europe/Africa |
2,797 | 2,841 | 2 | 3 | ||||||||||||
North America |
1,641 | 1,645 | | (9 | ) | |||||||||||
Latin America |
367 | 412 | 12 | 15 | ||||||||||||
Asia Pacific |
1,125 | 1,067 | (5 | ) | 4 | |||||||||||
Philips Group |
5,930 | 5,965 | 1 | 1 |
| Solid sales growth was visible across the emerging markets, led by Latin America, Eastern Europe, China and India, all of which recorded double-digit growth. Sales in Japan were lower than in Q1 2007 due to softer demand for Healthcare. |
| In North America, comparable sales declined by 9%, largely due to lower sales at Connected Displays. |
| Solid growth in Western Europe was moderated by lower sales at Connected Displays, which tempered the impact of growth in other businesses. |
5
Q1 | Q1 | |||||||
2007 | 2008 | |||||||
Healthcare |
119 | 121 | ||||||
Lighting |
186 | 200 | ||||||
Consumer Lifestyle |
141 | 77 | ||||||
Innovation & Emerging Businesses |
(31 | ) | (68 | ) | ||||
Group Management & Services |
(45 | ) | (65 | ) | ||||
Philips Group |
370 | 265 | ||||||
as a % of sales |
6.2 | 4.4 |
Q1 | Q1 | |||||||
2007 | 2008 | |||||||
Healthcare |
8.3 | 8.2 | ||||||
Lighting |
12.6 | 11.7 | ||||||
Consumer Lifestyle |
5.0 | 2.9 | ||||||
Innovation & Emerging Businesses |
(19.4 | ) | (86.1 | ) | ||||
Group Management & Services |
(91.8 | ) | (166.7 | ) | ||||
Philips Group |
6.2 | 4.4 |
Q1 | Q1 | |||||||
2007 | 2008 | |||||||
Healthcare |
73 | 77 | ||||||
Lighting |
177 | 158 | ||||||
Consumer Lifestyle |
138 | 73 | ||||||
Innovation & Emerging Businesses |
(31 | ) | (68 | ) | ||||
Group Management & Services |
(45 | ) | (65 | ) | ||||
Philips Group |
312 | 175 | ||||||
as a % of sales |
5.3 | 2.9 |
| EBITA amounted to EUR 265 million, or 4.4% of sales, EUR 105 million lower than in Q1 2007. Increased earnings at Lighting and Healthcare were more than offset by lower EBITA at Consumer Lifestyle, which saw a decline of EUR 64 million compared to Q1 2007, entirely due to Connected Displays and Optical Licenses. |
| Healthcare EBITA was slightly above Q1 2007 at EUR 121 million, or 8.2% of sales, including acquisition-related charges of approximately EUR 19 million. |
| Lighting EBITA increased by EUR 14 million to EUR 200 million, including acquisition-related charges of EUR 19 million. |
| Consumer Lifestyle EBITA declined by EUR 64 million to EUR 77 million, or 2.9% of sales. A EUR 44 million reduction in Connected Displays EBITA and EUR 30 million lower past-use optical license revenue more than offset moderate improvements in the rest of the business. |
| I&EB EBITA declined by EUR 37 million compared to Q1 2007, mainly due to EUR 20 million lower IP license revenues and a loss of EUR 13 million on the divestment of HTP Optics. |
| GM&S EBITA was EUR 20 million lower compared to the corresponding period of 2007, mainly due to pension-related costs and a different year-on-year spending pattern in corporate costs. |
6
Q1 | Q1 | |||||||
2007 | 2008 | |||||||
Interest expenses, net |
(13 | ) | (5 | ) | ||||
TSMC sale of securities |
733 | | ||||||
LG Display sale of securities |
| 83 | ||||||
TPV option fair-value adjustment |
(5 | ) | (26 | ) | ||||
Other |
(34 | ) | (6 | ) | ||||
681 | 46 |
| As a result of a higher average net cash position, net interest expenses were lower than in Q1 2007. |
| The sale of a further stake in LG Display yielded a net gain of EUR 83 million. The fair-value adjustment of the TPV bond options resulted in a loss of EUR 26 million. |
| Q1 2007 included a EUR 733 million gain on the sale of shares in TSMC, partly offset by a EUR 36 million loss on the market-value adjustment of JDS Uniphase. |
Q1 | Q1 | |||||||
2007 | 2008 | |||||||
LG Display |
(47 | ) | 66 | |||||
Other |
(2 | ) | (6 | ) | ||||
(49 | ) | 60 |
| Results relating to equity-accounted investees went from a EUR 49 million loss in Q1 2007 to a profit of EUR 60 million, entirely driven by improved operational results at LG Display. Effective March 1, Philips ceased equity accounting and going forward will account for its remaining stake in LG Display on a fair-value basis. |
7
Q1 | Q1 | |||||||
2007 | 2008 | |||||||
Cash of continuing operations |
5,886 | 8,769 | ||||||
Cash of discontinued operations |
137 | 108 | ||||||
Beginning balance |
6,023 | 8,877 | ||||||
Net cash from operating activities |
(194 | ) | (574 | ) | ||||
Gross capital expenditures |
(171 | ) | (176 | ) | ||||
Acquisitions/divestments |
(487 | ) | (5,213 | ) | ||||
Other cash from investing activities |
1,136 | 925 | ||||||
Repurchase of treasury shares |
(306 | ) | (967 | ) | ||||
Changes in debt/other |
(12 | ) | 1,904 | |||||
Net cash flow discontinued operations |
(83 | ) | (21 | ) | ||||
Ending balance |
5,906 | 4,755 | ||||||
Less cash of discontinued operations |
127 | 98 | ||||||
Cash of continuing operations |
5,779 | 4,657 |
| The Groups cash balance declined by EUR 4.1 billion as a result of the EUR 5.2 billion cash payments for acquisitions (Respironics, Genlyte and VISICU) and EUR 1.0 billion in share repurchases. Cash required for operating activities was some EUR 380 million higher than in Q1 2007. The issuance of bonds led to a cash inflow of EUR 2.0 billion, whereas the sale of 24 million shares in LG Display yielded cash proceeds of EUR 670 million. |
| Q1 2007s cash balance declined by EUR 117 million, as the acquisition of PLI (EUR 561 million), share repurchases of EUR 306 million and free gross cash flow requirements (EUR 365 million) were partly offset by EUR 1.1 billion receipts from the sale of shares in TSMC. |
| Cash required for operating activities was EUR 380 million higher than in Q1 2007, mainly caused by higher working capital and by last years sale of EUR 182 million of TSMC stock received as a dividend. Higher working capital requirements were mainly visible in the Consumer Lifestyle sector (principally inventories in Connected Displays) and in Healthcare (mainly accounts receivable due to a temporary delay in collection on the back of a change in IT systems). |
| Gross capital expenditures declined from EUR 152 million in Q1 2007 to EUR 148 million in Q1 2008. Expenditures were lower across all sectors with the exception of Lighting, where the inclusion of PLI and Genlyte led to higher investments compared to Q1 2007. |
8
| As a percentage of sales, inventories increased from 11.7% in Q1 2007 to 13.9%. Adjusting for the upward impact of recent acquisitions, inventories would have ended Q1 at a level of 12.9% of sales. The increase compared to Q1 2007 centered on Healthcare (Imaging and Service inventories) and Consumer Lifestyle (Connected Displays). |
| At the end of Q1, the Philips Group had net debt of EUR 0.7 billion, compared to a net cash position of EUR 5.2 billion at the beginning of the year. |
| The increase in net debt was mainly attributable to acquisition-related cash outflows totaling EUR 5.2 billion for Respironics, Genlyte and VISICU, as well as a further share repurchase of EUR 1.0 billion. The sale of 24 million shares in LG Display generated EUR 0.7 billion cash proceeds. |
| The EUR 1.4 billion reduction in equity is mainly the result of the EUR 1.0 billion repurchase of shares and the EUR 0.7 billion dividend payable, partially offset by the EUR 0.2 billion of net income. |
| Early March 2008, Philips placed USD 3.1 billion worth of Senior notes in order to refinance maturing debt. |
| Compared to Q4 2007, the increase in the number of employees includes an additional 11,966 from the recently completed acquisitions of Genlyte, VISICU and Respironics, partly offset by an employee reduction at Consumer Lifestyle and the divestment of HTP Optics in Q1 2008. |
9
Q1 | Q1 | |||||||
2007 | 2008 | |||||||
Sales |
1,431 | 1,474 | ||||||
Sales growth |
||||||||
% nominal |
3 | 3 | ||||||
% comparable |
4 | 5 | ||||||
EBITA |
119 | 121 | ||||||
as a % of sales |
8.3 | 8.2 | ||||||
EBIT |
73 | 77 | ||||||
as a % of sales |
5.1 | 5.2 | ||||||
Net operating capital (NOC) |
4,590 | 8,331 | ||||||
Number of employees (FTEs) |
27,204 | 34,645 |
| Strengthening its position in the fast-growing Chinese healthcare market, Philips closed a EUR 25 million deal with leading Chinese wholesaler Ascent Profit to sell digital radiography systems, and established a 7-year partnership with West China Hospital to jointly develop imaging procedures. |
| Philips announced two strategic acquisitions: Shenzhen Goldway Industrial in China, principally to strengthen its position in this key emerging market; and TOMCAT Systems in Northern Ireland, to expand the Healthcare Informatics business unit. |
| Philips completed the installation of its 50th Ambient Experience suite, at Fairview Hospital in Cleveland, Ohio, following other installations in various countries including the US, Saudi Arabia and Germany. |
Philips completed the acquisition of Respironics, the global leader in Obstructive Sleep Apnea treatment. Effective March 10, 2008, Respironics forms the centerpiece of Philips Home Healthcare portfolio. |
| Equipment order intake grew 9% on a currency-comparable basis compared to Q1 2007. Imaging Systems showed double-digit growth in North America, driven mainly by Magnetic Resonance, Nuclear Medicine and Cardiovascular X-Ray. |
| Comparable sales grew 5% year-on-year thanks to strong growth in Ultrasound, Cardiac Care, Patient Monitoring and Customer Services. The impact of the growth of these businesses was moderated by a weaker performance at Imaging Systems, which despite growth in some key modalities saw flat sales overall. |
| EBITA amounted to EUR 121 million, or 8.2% of sales, including EUR 19 million of integration and acquisition-related charges, mainly for Respironics, which reduced profitability by 1.3%. Higher earnings were seen in Ultrasound, Patient Monitoring and Customer Services, mainly driven by margin improvements and cost reductions, partially offset by lower earnings at Imaging Systems. |
| Net operating capital increased by EUR 3.7 billion compared to Q1 2007, largely due to the acquisitions and a temporary increase in receivables. |
| For the full year 2008, acquisition and integration charges related to Respironics, VISICU and Emergin are expected to negatively impact EBITA by approximately EUR 100 million, of which EUR 40 million in Q2. |
10
Q1 | Q1 | |||||||
2007 | 2008 | |||||||
Sales |
1,474 | 1,711 | ||||||
Sales growth |
||||||||
% nominal |
10 | 16 | ||||||
% comparable |
8 | 3 | ||||||
EBITA |
186 | 200 | ||||||
as a % of sales |
12.6 | 11.7 | ||||||
EBIT |
177 | 158 | ||||||
as a % of sales |
12.0 | 9.2 | ||||||
Net operating capital (NOC) |
3,441 | 5,999 | ||||||
Number of employees (FTEs) |
53,308 | 60,866 |
| At the Light + Building Fair held in Frankfurt, Germany, in early April, Philips presented a range of LED-based innovations for general illumination, especially for the home, offices, streets, the hospitality sector and shops. | |
| Philips announced that it plans to participate in a joint venture to set up a manufacturing facility and recycling plant for energy-saving compact fluorescent lamps in Lesotho, Southern Africa. | |
| Philips officially opened its Automotive Lighting Application Center at the Philips Innovation Campus in Shanghai, China. This center studies local needs in automotive lighting in order to provide customized support and speed up the introduction of the latest lighting technologies into the fast-growing local markets. | |
| Philips announced the completion of the acquisition of Genlyte, one of the leading North American luminaire manufacturers, which will help to further strengthen its leadership position in solid-state lighting. |
| Sales amounted to EUR 1,711 million on a comparable basis 3% higher than in Q1 2007 supported by strong growth of energy-efficient lighting solutions and growth in emerging markets, notably China, India and Latin America. This growth was tempered by lower sales in UHP, backlighting and Lumileds, the latter having executed a product recall earlier in the quarter. | |
| The recent strategic acquisitions of Genlyte, Color Kinetics, LTI and PLI all contributed positively to both sales and earnings in line with expectations. | |
| EBITA increased by EUR 14 million year-on-year albeit with increased spending on solid-state lighting solutions and temporary softness in Western European markets and included restructuring, acquisition-related and other incidental charges amounting to EUR 35 million. Q1 2007 included charges totaling EUR 34 million. | |
| The increase in both net operating capital and employees is mainly related to the acquisitions of Genlyte and Color Kinetics. |
| Restructuring and acquisition-related charges are expected to amount to approximately EUR 20 million in Q2 2008. |
11
Q1 | Q1 | |||||||
2007 | 2008 | |||||||
Sales |
2,816 | 2,662 | ||||||
of which Connected Displays |
1,293 | 1,227 | ||||||
Sales growth |
||||||||
% nominal |
(4 | ) | (5 | ) | ||||
% comparable |
(2 | ) | | |||||
Sales growth excl. Connected Displays |
||||||||
% nominal |
6 | (6 | ) | |||||
% comparable |
6 | | ||||||
EBITA |
141 | 77 | ||||||
of which Connected Displays |
(51 | ) | (95 | ) | ||||
as a % of sales |
5.0 | 2.9 | ||||||
EBIT |
138 | 73 | ||||||
of which Connected Displays |
(51 | ) | (95 | ) | ||||
as a % of sales |
4.9 | 2.7 | ||||||
Net operating capital (NOC) |
1,337 | 1,398 | ||||||
of which Connected Displays |
43 | 28 | ||||||
Number of employees (FTEs) |
24,009 | 21,868 | ||||||
of which Connected Displays |
7,329 | 6,720 |
| Philips intends to enter into a 5-year licensing agreement under which Funai will assume the sourcing, distribution, marketing and sales of all Philips consumer television activities in the US and Canada, effective September 2008. | |
| In March, Philips sold its one-millionth Whole Fruit Juicer, underscoring the ongoing success of our Healthy Living initiatives, which continue to drive strong double-digit growth in our Domestic Appliances business. | |
| In the US, Philips entered into a multi-year partnership with Bliss, an international beauty brand, launching an at-home hair removal kit. | |
| In January 2008, Philips Sonicare launched the HealthyWhite whitening toothbrush in Europe, bringing the Flexcare range of products to full complement in the European market. |
| On a comparable basis, sales at Consumer Lifestyle were on par with Q1 2007. At Connected Displays, comparable sales declined by 2%, as a result of the continued focus on margin management. Sales levels at most other operational businesses were in line with or higher than Q1 2007, with the strongest growth visible at Domestic Appliances, Shaving & Beauty and Peripherals & Accessories. | |
| From a geographical perspective, comparable sales growth was particularly strong in emerging markets. | |
| EBITA declined by EUR 64 million to EUR 77 million, or 2.9% of sales. A EUR 44 million reduction in Connected Displays EBITA and EUR 30 million lower past-use optical license revenue more than offset moderate improvements in the rest of the business. | |
| Profitability at the remaining Consumer Lifestyle businesses, notably Domestic Appliances, Shaving & Beauty and Video & Multimedia Applications, remained strong. |
| Margin pressure at Connected Displays is expected to continue. | |
| Actions to structurally improve the profitability of Connected Displays will continue, resulting in total financial charges of up to EUR 125 million in 2008. | |
| The sale of the Set-Top Box and Connectivity Solutions activities is now expected to close in Q2 2008. |
12
Q1 | Q1 | |||||||
2007 | 2008 | |||||||
Sales |
160 | 79 | ||||||
Sales growth |
||||||||
% nominal |
(60 | ) | (51 | ) | ||||
% comparable |
40 | (22 | ) | |||||
EBITA Technologies / Incubators |
(30 | ) | (46 | ) | ||||
EBITA others |
(1 | ) | (22 | ) | ||||
EBITA |
(31 | ) | (68 | ) | ||||
EBIT |
(31 | ) | (68 | ) | ||||
Net operating capital (NOC) |
155 | 216 | ||||||
Number of employees (FTEs) |
6,500 | 5,608 |
| Philips Research announced that it is spearheading the HeartCycle consortium, comprising 18 research, academic, industrial and medical organizations from nine different European countries and China. The consortium aims to improve the quality of life for coronary heart disease and heart failure patients. | |
| At EuroShop 2008, Philips Research showcased a selection of new lighting solutions that enable interactive product presentations and quick-and-easy atmosphere creation for retailers. | |
| Philips received the coveted Gold iF product design award for the EcoClassic50/MASTERClassic energy-saving lamp, completing an extremely successful participation in this prestigious international design competition, in which Philips collected a total of 27 awards. |
| The EBITA decline compared to Q1 2007 was primarily due to a EUR 13 million loss on the sale of HTP Optics and lower IP license revenues. Q1 2007 EBITA included a EUR 6 million gain on the sale of TASS. | |
| The year-on-year increase in net operating capital was attributable to the divestment of businesses which operated with negative working capital. | |
| Compared to Q1 2007, the reduction in the number of employees was mainly due to the divestment of businesses over the past 12 months. |
| Further investment in Research and the Incubators is expected to result in an average quarterly spend of EUR 40 million for the remainder of 2008. |
13
Q1 | Q1 | |||||||
2007 | 2008 | |||||||
Sales |
49 | 39 | ||||||
Sales growth |
||||||||
% nominal |
82 | (20 | ) | |||||
% comparable |
96 | (22 | ) | |||||
EBITA Corporate & Regional Costs |
(33 | ) | (42 | ) | ||||
EBITA Brand Campaign |
(2 | ) | (5 | ) | ||||
EBITA Service Units, Pensions and Other |
(10 | ) | (18 | ) | ||||
EBITA |
(45 | ) | (65 | ) | ||||
EBIT |
(45 | ) | (65 | ) | ||||
Net operating capital (NOC) |
425 | 987 | ||||||
Number of employees (FTEs) |
6,956 | 5,628 |
| On the publication of its tenth Sustainability Report, Philips announced a one-third increase in Green Product sales to EUR 5.3 billion. Green Product sales now make up 20% of total sales, with strong contributions from the Consumer Lifestyle and Healthcare sectors as well as Lighting. | |
| SAM Research, the leading asset manager for sustainability investments, which identifies leaders for the Dow Jones Sustainability Indexes, named Philips a SAM Gold Class world leader in its Sustainability Yearbook 2008 and SAM Sector Leader in our industry group. | |
| Philips was named as a winner in the 2008 Investor Relations Global Rankings in the categories best corporate governance practices and best Investor Relations website. |
| The EBITA decline of Corporate & Regional overheads compared to Q1 2007 was mainly due to a different seasonal pattern in overhead-related project spend. | |
| Costs of pensions and other post-retirement benefits increased compared to Q1 2007. | |
| The year-on-year increase in net operating capital was primarily related to prepaid pension assets. |
| Investment in the brand campaign is expected to total approximately EUR 20 million in Q2 2008 and EUR 70 million for the full year. |
| For the full year, Corporate and Regional overhead costs are expected to be lower than in 2007. |
| Costs of pensions and other post-retirement benefit plans for each of the next three quarters are anticipated to be broadly in line with Q1 2008, implying a limited nominal increase for the full year. |
14
| Our Group-level EBITA margin is now expected to be in the range of 10 11% in 2010, with average annual sales growth of above 6%. | |
| This Group EBITA target is underpinned by the following 2010 EBITA margins per sector: |
| Healthcare | 15 17% | ||||
| Lighting | 12 14% | ||||
| Consumer Lifestyle | 8 10% |
| We confirm our objective to more than double EBITA per share by 2010 from the 2007 level. | |
| We expect our return on invested capital (ROIC) to reach 12 13% by the year 2010, significantly above our current ROIC level, which has been negatively impacted by the increase in our asset base driven by recent acquisitions. |
15
January to March | ||||||||
2007 | 2008 | |||||||
Sales |
5,930 | 5,965 | ||||||
Cost of sales |
(3,939 | ) | (3,992 | ) | ||||
Gross margin |
1,991 | 1,973 | ||||||
Selling expenses |
(1,112 | ) | (1,143 | ) | ||||
General and administrative expenses |
(212 | ) | (236 | ) | ||||
Research and development expenses |
(403 | ) | (409 | ) | ||||
Other business income and expenses |
48 | (10 | ) | |||||
Income from operations |
312 | 175 | ||||||
Financial income and expenses |
681 | 46 | ||||||
Income before taxes |
993 | 221 | ||||||
Income tax expense |
(92 | ) | (49 | ) | ||||
Income after taxes |
901 | 172 | ||||||
Results relating to equity-accounted investees |
(49 | ) | 60 | |||||
Minority interests |
| | ||||||
Income from continuing operations |
852 | 232 | ||||||
Discontinued operations |
23 | (13 | ) | |||||
Net income |
875 | 219 | ||||||
Weighted average number of common shares
outstanding (after deduction of treasury
stock) during the period (in thousands): |
||||||||
basic |
1,100,107 | 1,048,432 | ||||||
diluted |
1,111,232 | 1,058,696 | ||||||
Net income per common share in euros: |
||||||||
basic |
0.80 | 0.21 | ||||||
diluted |
0.79 | 0.21 | ||||||
Ratios |
||||||||
Gross margin as a % of sales |
33.6 | 33.1 | ||||||
Selling expenses as a % of sales |
(18.8 | ) | (19.2 | ) | ||||
G&A expenses as a % of sales |
(3.6 | ) | (4.0 | ) | ||||
R&D expenses as a % of sales |
(6.8 | ) | (6.9 | ) | ||||
EBIT or Income from operations |
312 | 175 | ||||||
as a % of sales |
5.3 | 2.9 | ||||||
EBITA |
370 | 265 | ||||||
as a % of sales |
6.2 | 4.4 |
16
March 31, | December 31, | March 31, | ||||||||||
2007 | 2007 | 2008 | ||||||||||
Current assets: |
||||||||||||
Cash and cash equivalents |
5,779 | 8,769 | 4,657 | |||||||||
Receivables |
4,287 | 4,670 | 4,773 | |||||||||
Current assets of discontinued operations |
206 | 169 | 156 | |||||||||
Inventories |
3,108 | 3,203 | 3,717 | |||||||||
Other current assets |
1,341 | 1,020 | 1,392 | |||||||||
Total current assets |
14,721 | 17,831 | 14,695 | |||||||||
Non-current assets: |
||||||||||||
Investments in equity-accounted investees |
2,811 | 1,886 | 252 | |||||||||
Other non-current financial assets |
6,744 | 3,183 | 4,481 | |||||||||
Non-current receivables |
222 | 84 | 83 | |||||||||
Non-current assets of discontinued operations |
221 | 164 | 154 | |||||||||
Other non-current assets |
3,520 | 3,726 | 3,756 | |||||||||
Property, plant and equipment |
3,144 | 3,180 | 3,419 | |||||||||
Intangible assets excluding goodwill |
2,011 | 2,154 | 3,839 | |||||||||
Goodwill |
3,945 | 4,135 | 7,266 | |||||||||
Total assets |
37,339 | 36,343 | 37,945 | |||||||||
Current liabilities: |
||||||||||||
Accounts and notes payable |
2,755 | 3,372 | 2,939 | |||||||||
Current liabilities of discontinued operations |
53 | 46 | 44 | |||||||||
Accrued liabilities |
3,347 | 2,984 | 3,168 | |||||||||
Short-term provisions |
684 | 377 | 405 | |||||||||
Other current liabilities |
561 | 509 | 460 | |||||||||
Dividend payable |
659 | | 720 | |||||||||
Short-term debt |
1,006 | 2,345 | 2,234 | |||||||||
Total current liabilities |
9,065 | 9,633 | 9,970 | |||||||||
Non-current liabilities: |
||||||||||||
Long-term debt |
2,928 | 1,212 | 3,171 | |||||||||
Non-current liabilities of discontinued operations |
2,547 | 111 | 102 | |||||||||
Long-term provisions |
116 | 2,727 | 3,498 | |||||||||
Other non-current liabilities |
666 | 934 | 935 | |||||||||
Total liabilities |
15,322 | 14,617 | 17,676 | |||||||||
Minority interests |
48 | 42 | 41 | |||||||||
Stockholders equity |
21,969 | 21,684 | 20,228 | |||||||||
Total liabilities and equity |
37,339 | 36,343 | 37,945 | |||||||||
Number of common shares outstanding (after deduction of treasury stock)
at the end of period (in thousands) |
1,097,563 | 1,064,893 | 1,028,349 | |||||||||
Ratios |
||||||||||||
Stockholders equity per common share in euros |
20.02 | 20.36 | 19.67 | |||||||||
Inventories as a % of sales |
11.7 | 12.0 | 13.9 | |||||||||
Net debt (cash): group equity |
(9):109 | (32):132 | 4:96 | |||||||||
Net operating capital |
9,948 | 10,586 | 16,931 | |||||||||
Employees at end of period |
124,298 | 123,801 | 134,212 | |||||||||
of which discontinued operations |
6,321 | 5,703 | 5,597 |
17
January to March | ||||||||
2007 | 2008 | |||||||
Cash flows from operating activities: |
||||||||
Net income |
875 | 219 | ||||||
(Income) loss discontinued operations |
(23 | ) | 13 | |||||
Adjustments to reconcile income to net cash provided by (used for) operating activities: |
||||||||
Depreciation and amortization |
204 | 252 | ||||||
Impairment of goodwill, equity-accounted investees and available-for-sale securities |
39 | | ||||||
Net gain on sale of assets |
(774 | ) | (69 | ) | ||||
(Income) loss from equity-accounted investees (net of dividends received) |
87 | (9 | ) | |||||
Minority interests (net of dividends paid) |
| | ||||||
(Increase) decrease in working capital/other current assets |
(597 | ) | (1,002 | ) | ||||
(Increase) decrease in non-current receivables/other assets/other liabilities |
(287 | ) | (58 | ) | ||||
Increase (decrease) in provisions |
80 | 78 | ||||||
Proceeds from sales of trading securities |
182 | | ||||||
Other items |
20 | 2 | ||||||
Net cash provided by (used for) operating activities |
(194 | ) | (574 | ) | ||||
Cash flows from investing activities: |
||||||||
Purchase of intangible assets |
(19 | ) | (28 | ) | ||||
Capital expenditures on property, plant and equipment |
(152 | ) | (148 | ) | ||||
Proceeds from disposals of property, plant and equipment |
10 | 4 | ||||||
Cash from (to) derivatives |
(15 | ) | 184 | |||||
Proceeds from sale (purchase) of other non-current financial assets |
1,141 | 737 | ||||||
Proceeds from sale (purchase) of businesses |
(487 | ) | (5,213 | ) | ||||
Net cash provided by (used for) investing activities |
478 | (4,464 | ) | |||||
Cash flows from financing activities: |
||||||||
Increase (decrease) in debt |
2 | 1,959 | ||||||
Treasury stock transactions |
(306 | ) | (967 | ) | ||||
Net cash provided by (used for) financing activities |
(304 | ) | 992 | |||||
Net cash provided by (used for) continuing operations |
(20 | ) | (4,046 | ) | ||||
Cash flows from discontinued operations: |
||||||||
Net cash provided by (used for) operating activities |
(83 | ) | (21 | ) | ||||
Net cash provided by (used for) discontinued operations |
(83 | ) | (21 | ) | ||||
Net cash provided by (used for) continuing and discontinued operations |
(103 | ) | (4,067 | ) | ||||
Effect of change in exchange rates on cash positions |
(14 | ) | (55 | ) | ||||
Cash and cash equivalents at beginning of period |
6,023 | 8,877 | ||||||
Cash and cash equivalents at end of period |
5,906 | 4,755 | ||||||
Less cash of discontinued operations at end of period |
127 | 98 | ||||||
Cash of continuing operations at end of period |
5,779 | 4,657 | ||||||
* | For a number of reasons, principally the effects of translation differences, certain items in the statements of cash flows do not correspond to the differences between the balance sheet amounts for the respective items. |
Ratio |
||||||||
Cash flows before financing activities |
284 | (5,038 | ) |
18
accumulated other comprehensive income (loss) | Q1 2008 | |||||||||||||||||||||||||||||||||||||||
capital in | unrealized gain | changes in | total | |||||||||||||||||||||||||||||||||||||
excess | currency | (loss) on | fair value of | treasury | stock- | |||||||||||||||||||||||||||||||||||
common | of par | retained | translation | available-for- | pensions | cash flow | shares at | holders | ||||||||||||||||||||||||||||||||
stock | value | earnings | differences | sale securities | (FAS 158) | hedges | total | cost | equity | |||||||||||||||||||||||||||||||
Balance as of December 31, 2007 |
228 | | 25,559 | (2,373 | ) | 1,048 | (590 | ) | 28 | (1,887 | ) | (2,216 | ) | 21,684 | ||||||||||||||||||||||||||
Net income |
219 | 219 | ||||||||||||||||||||||||||||||||||||||
Net current period change |
(284 | ) | 309 | 44 | 5 | 74 | 74 | |||||||||||||||||||||||||||||||||
Reclassifications into income |
11 | (99 | ) | (10 | ) | (98 | ) | (98 | ) | |||||||||||||||||||||||||||||||
Total comprehensive income (loss), net of tax |
219 | (273 | ) | 210 | 44 | (5 | ) | (24 | ) | 195 | ||||||||||||||||||||||||||||||
Dividend payable |
(720 | ) | (720 | ) | ||||||||||||||||||||||||||||||||||||
Cancellation of treasury stock |
(11 | ) | (1,707 | ) | 1,718 | | ||||||||||||||||||||||||||||||||||
Purchase of treasury stock |
(974 | ) | (974 | ) | ||||||||||||||||||||||||||||||||||||
Re-issuance of treasury stock |
(1 | ) | 17 | 16 | ||||||||||||||||||||||||||||||||||||
Share-based compensation plans |
27 | 27 | ||||||||||||||||||||||||||||||||||||||
Balance as of March 31, 2008 |
217 | 26 | 23,351 | (2,646 | ) | 1,258 | (546 | ) | 23 | (1,911 | ) | (1,455 | ) | 20,228 |
19
1st quarter | ||||||||||||||||||||||||
2007 | 2008 | |||||||||||||||||||||||
income from operations | income from operations | |||||||||||||||||||||||
as % of | as % of | |||||||||||||||||||||||
sales | amount | sales | sales | amount | sales | |||||||||||||||||||
Healthcare |
1,431 | 73 | 5.1 | 1,474 | 77 | 5.2 | ||||||||||||||||||
Lighting |
1,474 | 177 | 12.0 | 1,711 | 158 | 9.2 | ||||||||||||||||||
Consumer Lifestyle* |
2,816 | 138 | 4.9 | 2,662 | 73 | 2.7 | ||||||||||||||||||
Innovation & Emerging
Businesses |
160 | (31 | ) | (19.4 | ) | 79 | (68 | ) | (86.1 | ) | ||||||||||||||
Group Management & Services |
49 | (45 | ) | (91.8 | ) | 39 | (65 | ) | (166.7 | ) | ||||||||||||||
5,930 | 312 | 5.3 | 5,965 | 175 | 2.9 | |||||||||||||||||||
* of which Connected Displays |
1,293 | (51 | ) | (3.9 | ) | 1,227 | (95 | ) | (7.7 | ) |
20
sales | total assets | |||||||||||||||
January to March | March 31, | |||||||||||||||
2007 | 2008 | 2007 | 2008 | |||||||||||||
Healthcare |
1,431 | 1,474 | 6,626 | 10,507 | ||||||||||||
Lighting |
1,474 | 1,711 | 4,696 | 7,399 | ||||||||||||
Consumer Lifestyle |
2,816 | 2,662 | 4,005 | 4,102 | ||||||||||||
Innovation & Emerging Businesses |
160 | 79 | 613 | 520 | ||||||||||||
Group Management & Services |
49 | 39 | 20,972 | 15,107 | ||||||||||||
5,930 | 5,965 | 36,912 | 37,635 | |||||||||||||
Discontinued operations |
427 | 310 | ||||||||||||||
37,339 | 37,945 |
sales | long-lived assets * | |||||||||||||||
January to March | March 31, | |||||||||||||||
2007 | 2008 | 2007 | 2008 | |||||||||||||
United States |
1,559 | 1,511 | 4,831 | 10,414 | ||||||||||||
Germany |
441 | 481 | 289 | 285 | ||||||||||||
China |
420 | 444 | 165 | 156 | ||||||||||||
France |
366 | 391 | 104 | 104 | ||||||||||||
United Kingdom |
279 | 270 | 784 | 676 | ||||||||||||
Netherlands |
255 | 261 | 1,171 | 1,246 | ||||||||||||
Other countries |
2,610 | 2,607 | 1,756 | 1,643 | ||||||||||||
5,930 | 5,965 | 9,100 | 14,524 |
* | Includes property, plant and equipment and intangible assets |
21
January to March 2008 | ||||||||
Netherlands | other | |||||||
Service cost |
34 | 23 | ||||||
Interest cost on the projected benefit obligation |
131 | 100 | ||||||
Expected return on plan assets |
(192 | ) | (94 | ) | ||||
Net actuarial (gain) loss |
(4 | ) | 15 | |||||
Prior service cost (income) |
(11 | ) | 2 | |||||
Net periodic cost (income) |
(42 | ) | 46 |
January to March 2008 | ||||||||
Netherlands | other | |||||||
Service cost |
| 1 | ||||||
Interest cost on the accumulated postretirement benefit obligation |
| 8 | ||||||
Translation obligation |
| 1 | ||||||
Net actuarial loss |
| 2 | ||||||
Net periodic cost |
| 12 |
22
January to March | ||||||||
2007 | 2008 | |||||||
Sales |
5,930 | 5,965 | ||||||
Cost of sales |
(3,945 | ) | (4,001 | ) | ||||
Gross margin |
1,985 | 1,964 | ||||||
Selling expenses |
(1,112 | ) | (1,142 | ) | ||||
General and administrative expenses |
(197 | ) | (236 | ) | ||||
Research and development expenses |
(395 | ) | (387 | ) | ||||
Other business income and expenses |
17 | (14 | ) | |||||
Income from operations |
298 | 185 | ||||||
Financial income and expenses |
679 | 119 | ||||||
Income before taxes |
977 | 304 | ||||||
Income tax expense |
(91 | ) | (57 | ) | ||||
Income after taxes |
886 | 247 | ||||||
Results relating to equity-accounted investees |
(46 | ) | 59 | |||||
Minority interests |
| | ||||||
Income from continuing operations |
840 | 306 | ||||||
Discontinued operations |
23 | (13 | ) | |||||
Net income |
863 | 293 | ||||||
Weighted average number of common shares outstanding
(after deduction
of treasury stock) during the period (in thousands): |
||||||||
basic |
1,100,107 | 1,048,432 | ||||||
diluted |
1,111,459 | 1,058,960 | ||||||
Net income per common share in euros: |
||||||||
basic |
0.78 | 0.28 | ||||||
diluted |
0.78 | 0.28 | ||||||
Ratios |
||||||||
Gross margin as a % of sales |
33.5 | 32.9 | ||||||
Selling expenses as a % of sales |
(18.8 | ) | (19.1 | ) | ||||
G&A expenses as a % of sales |
(3.3 | ) | (4.0 | ) | ||||
R&D expenses as a % of sales |
(6.7 | ) | (6.5 | ) | ||||
EBIT or Income from operations |
298 | 185 | ||||||
as a % of sales |
5.0 | 3.1 | ||||||
EBITA |
355 | 256 | ||||||
as a % of sales |
6.0 | 4.3 |
23
March 31, | December 31, | March 31, | ||||||||||
2007 | 2007 | 2008 | ||||||||||
Current assets: |
||||||||||||
Cash and cash equivalents |
5,779 | 8,769 | 4,657 | |||||||||
Receivables |
4,287 | 4,670 | 4,773 | |||||||||
Current assets of discontinued operations |
206 | 149 | 156 | |||||||||
Inventories |
3,108 | 3,203 | 3,717 | |||||||||
Other current assets |
697 | 622 | 867 | |||||||||
Total current assets |
14,077 | 17,413 | 14,170 | |||||||||
Non-current assets: |
||||||||||||
Investments in equity-accounted investees |
2,711 | 1,817 | 254 | |||||||||
Other non-current financial assets |
6,744 | 3,183 | 4,481 | |||||||||
Non-current receivables |
214 | 78 | 78 | |||||||||
Non-current assets of discontinued operations |
218 | 170 | 140 | |||||||||
Other non-current assets |
2,360 | 2,512 | 2,684 | |||||||||
Deferred tax assets |
1,571 | 1,271 | 1,362 | |||||||||
Property, plant and equipment |
3,159 | 3,194 | 3,430 | |||||||||
Intangible assets excluding goodwill |
2,725 | 2,835 | 4,514 | |||||||||
Goodwill |
3,633 | 3,800 | 6,940 | |||||||||
Total assets |
37,412 | 36,273 | 38,053 | |||||||||
Current liabilities: |
||||||||||||
Accounts and notes payable |
2,755 | 3,372 | 2,939 | |||||||||
Current liabilities of discontinued operations |
53 | 46 | 44 | |||||||||
Accrued liabilities |
3,329 | 2,975 | 3,135 | |||||||||
Short-term provisions |
689 | 382 | 357 | |||||||||
Other current liabilities |
561 | 509 | 460 | |||||||||
Dividend payable |
659 | | 720 | |||||||||
Short-term debt |
1,012 | 2,350 | 2,237 | |||||||||
Total current liabilities |
9,058 | 9,634 | 9,892 | |||||||||
Non-current liabilities: |
||||||||||||
Long-term debt |
2,929 | 1,213 | 3,172 | |||||||||
Long-term provisions |
1,902 | 2,021 | 2,001 | |||||||||
Deferred tax liabilities |
707 | 667 | 1,571 | |||||||||
Non-current liabilities of discontinued operations |
29 | 32 | 30 | |||||||||
Other non-current liabilities |
549 | 796 | 900 | |||||||||
Total liabilities |
15,174 | 14,363 | 17,566 | |||||||||
Minority interests * |
140 | 127 | 119 | |||||||||
Stockholders equity |
22,098 | 21,783 | 20,368 | |||||||||
Total liabilities and equity |
37,412 | 36,273 | 38,053 | |||||||||
Number of common shares outstanding (after deduction of treasury stock)
at the end of period (in thousands) |
1,097,563 | 1,064,893 | 1,028,349 | |||||||||
Ratios |
||||||||||||
Stockholders equity per common share in euros |
20.13 | 20.46 | 19.81 | |||||||||
Inventories as a % of sales |
11.7 | 12.0 | 13.9 | |||||||||
Net debt (cash): group equity |
(9):109 | (31):131 | 4:96 | |||||||||
Employees at end of period |
124,298 | 123,801 | 134,212 | |||||||||
of which discontinued operations |
6,321 | 5,703 | 5,597 |
* | of which discontinued operations EUR 87 million end of March 2007 and EUR 79 million end of December 2007 |
24
January to | March | |||||||
2007 | 2008 | |||||||
Net income as per the consolidated statements of income on a
US GAAP basis |
875 | 219 | ||||||
Adjustments to IFRS: |
||||||||
Capitalized product development expenses |
46 | 59 | ||||||
Amortization of product development assets |
(47 | ) | (35 | ) | ||||
Pensions and other postretirement benefits |
15 | 7 | ||||||
Amortization of intangible assets |
(7 | ) | (7 | ) | ||||
Provisions |
2 | (11 | ) | |||||
Financial income and expenses |
(2 | ) | 73 | |||||
Equity accounted investees |
3 | (1 | ) | |||||
Deferred income tax effects |
1 | (8 | ) | |||||
Other differences in income |
(23 | ) | (3 | ) | ||||
Net income in accordance with IFRS |
863 | 293 |
March 31, | March 31, | |||||||
2007 | 2008 | |||||||
Stockholders equity as per the consolidated balance sheets on a
US GAAP basis |
21,969 | 20,228 | ||||||
Adjustments to IFRS: |
||||||||
Product development expenses |
513 | 530 | ||||||
Pensions and other postretirement benefits |
(78 | ) | (143 | ) | ||||
Goodwill amortization (until January 1, 2004) |
(283 | ) | (242 | ) | ||||
Goodwill capitalization (acquisition-related) |
(29 | ) | (84 | ) | ||||
Acquisition-related intangibles |
201 | 146 | ||||||
Investments in equity-accounted investees |
(100 | ) | 2 | |||||
Recognized results on sale-and-leaseback transactions |
49 | 36 | ||||||
Provisions |
55 | 3 | ||||||
Deferred income tax effects |
(206 | ) | (117 | ) | ||||
Assets from discontinued operations |
(3 | ) | (14 | ) | ||||
Other differences in equity |
10 | 23 | ||||||
Stockholders equity in accordance with IFRS |
22,098 | 20,368 |
25
January to March | ||||||||||||||||
comparable | currency | consolidation | nominal | |||||||||||||
growth | effects | changes | growth | |||||||||||||
2008 versus 2007 |
||||||||||||||||
Healthcare |
4.7 | (7.6 | ) | 5.9 | 3.0 | |||||||||||
Lighting |
2.7 | (4.4 | ) | 17.8 | 16.1 | |||||||||||
Consumer Lifestyle |
(0.5 | ) | (3.7 | ) | (1.3 | ) | (5.5 | ) | ||||||||
Innovation & Emerging Businesses |
(21.8 | ) | (2.0 | ) | (26.8 | ) | (50.6 | ) | ||||||||
Group Management & Services |
(22.0 | ) | 1.6 | | (20.4 | ) | ||||||||||
Philips Group |
1.0 | (4.7 | ) | 4.3 | 0.6 |
Philips | Consumer | |||||||||||||||||||||||
Group | Healthcare | Lighting | Lifestyle | I&EB | GM&S | |||||||||||||||||||
January to March 2008 |
||||||||||||||||||||||||
EBITA |
265 | 121 | 200 | 77 | (68 | ) | (65 | ) | ||||||||||||||||
Amortization of intangibles (excl. software) |
(71 | ) | (39 | ) | (28 | ) | (4 | ) | | | ||||||||||||||
Write-off of acquired in-process R&D |
(19 | ) | (5 | ) | (14 | ) | | | | |||||||||||||||
Income from operations (or EBIT) |
175 | 77 | 158 | 73 | (68 | ) | (65 | ) | ||||||||||||||||
January to March 2007 |
||||||||||||||||||||||||
EBITA |
370 | 119 | 186 | 141 | (31 | ) | (45 | ) | ||||||||||||||||
Amortization of intangibles (excl. software) |
(48 | ) | (36 | ) | (9 | ) | (3 | ) | | | ||||||||||||||
Write-off of acquired in-process R&D |
(10 | ) | (10 | ) | | | | | ||||||||||||||||
Income from operations (or EBIT) |
312 | 73 | 177 | 138 | (31 | ) | (45 | ) |
March 31, | March 31, | |||||||
2007 | 2008 | |||||||
Long-term debt |
2,928 | 3,171 | ||||||
Short-term debt |
1,006 | 2,234 | ||||||
Total debt |
3,934 | 5,405 | ||||||
Cash and cash equivalents |
5,779 | 4,657 | ||||||
Net debt (cash) (total debt less cash and cash equivalents) |
(1,845 | ) | 748 | |||||
Minority interests |
48 | 41 | ||||||
Stockholders equity |
21,969 | 20,228 | ||||||
Group equity |
22,017 | 20,269 | ||||||
Net debt and group equity |
20,172 | 21,017 | ||||||
Net debt (cash) divided by net debt (cash) and group equity (in %) |
(9 | ) | 4 | |||||
Group equity divided by net debt (cash) and group equity (in %) |
109 | 96 |
26
Consumer | ||||||||||||||||||||||||
Philips Group | Healthcare | Lighting | Lifestyle | I&EB | GM&S | |||||||||||||||||||
March 31, 2008 |
||||||||||||||||||||||||
Net operating capital (NOC) |
16,931 | 8,331 | 5,999 | 1,398 | 216 | 987 | ||||||||||||||||||
Exclude liabilities comprised in NOC: |
||||||||||||||||||||||||
payables/liabilities |
7,502 | 1,863 | 1,203 | 2,372 | 214 | 1,850 | ||||||||||||||||||
intercompany accounts |
| 28 | 53 | 75 | (24 | ) | (132 | ) | ||||||||||||||||
provisions 1) |
2,356 | 233 | 134 | 255 | 30 | 1,704 | ||||||||||||||||||
Include assets not comprised in NOC: |
||||||||||||||||||||||||
investments in equity-accounted
investees |
252 | 52 | 10 | 2 | 84 | 104 | ||||||||||||||||||
other non-current financial assets |
4,481 | | | | | 4,481 | ||||||||||||||||||
deferred tax assets |
1,456 | | | | | 1,456 | ||||||||||||||||||
liquid assets |
4,657 | | | | | 4,657 | ||||||||||||||||||
Total assets of continuing operations |
37,635 | 10,507 | 7,399 | 4,102 | 520 | 15,107 | ||||||||||||||||||
Assets of discontinued operations |
310 | |||||||||||||||||||||||
Total assets |
37,945 |
1) | provisions on balance sheet EUR 3,903 million excluding deferred tax liabilities of EUR 1,547 million |
March 31, 2007 |
||||||||||||||||||||||||
Net operating capital (NOC) |
9,948 | 4,590 | 3,441 | 1,337 | 155 | 425 | ||||||||||||||||||
Exclude liabilities comprised in NOC: |
||||||||||||||||||||||||
payables/liabilities |
7,329 | 1,716 | 1,047 | 2,277 | 304 | 1,985 | ||||||||||||||||||
intercompany accounts |
46 | 44 | 75 | (39 | ) | (126 | ) | |||||||||||||||||
provisions 2) |
2,648 | 232 | 152 | 316 | 64 | 1,884 | ||||||||||||||||||
Include assets not comprised in NOC: |
||||||||||||||||||||||||
investments in equity-accounted investees |
2,811 | 42 | 12 | 129 | 2,628 | |||||||||||||||||||
other non-current financial assets |
6,744 | | | | | 6,744 | ||||||||||||||||||
deferred tax assets |
1,653 | | | | | 1,653 | ||||||||||||||||||
liquid assets |
5,779 | | | | | 5,779 | ||||||||||||||||||
Total assets of continuing operations |
36,912 | 6,626 | 4,696 | 4,005 | 613 | 20,972 | ||||||||||||||||||
Assets of discontinued operations |
427 | |||||||||||||||||||||||
Total assets |
37,339 |
2) | provisions on balance sheet EUR 3,231 million excluding deferred tax liabilities of EUR 583 million |
Composition of cash flows before financing activities continuing operations |
January to March | ||||||||
2007 | 2008 | |||||||
Cash flows used for operating activities |
(194 | ) | (574 | ) | ||||
Cash flows provided by (used for) investing activities |
478 | (4,464 | ) | |||||
Cash flows before financing activities |
284 | (5,038 | ) |
27
2007 | 2008 | |||||||||||||||||||||||||||||||
1st | 2nd | 3rd | 4th | 1st | 2nd | 3rd | 4th | |||||||||||||||||||||||||
quarter | quarter | quarter | quarter | quarter | quarter | quarter | quarter | |||||||||||||||||||||||||
Sales |
5,930 | 6,033 | 6,465 | 8,365 | 5,965 | |||||||||||||||||||||||||||
% increase |
(2 | ) | (4 | ) | 4 | 4 | 1 | |||||||||||||||||||||||||
EBITA |
370 | 394 | 436 | 865 | 265 | |||||||||||||||||||||||||||
as a % of sales |
6.2 | 6.5 | 6.7 | 10.3 | 4.4 | |||||||||||||||||||||||||||
EBIT |
312 | 345 | 385 | 810 | 175 | |||||||||||||||||||||||||||
as a % of sales |
5.3 | 5.7 | 6.0 | 9.7 | 2.9 | |||||||||||||||||||||||||||
Net income |
875 | 1,569 | 331 | 1,393 | 219 | |||||||||||||||||||||||||||
per common share in euros |
0.80 | 1.43 | 0.31 | 1.31 | 0.21 |
January- | January- | January- | January- | January- | January- | January- | January- | |||||||||||||||||||||||||
March | June | September | December | March | June | September | December | |||||||||||||||||||||||||
Sales |
5,930 | 11,963 | 18,428 | 26,793 | 5,965 | |||||||||||||||||||||||||||
% increase |
(2 | ) | (3 | ) | (1 | ) | 1 | |||||||||||||||||||||||||
EBITA |
370 | 764 | 1,200 | 2,065 | 265 | |||||||||||||||||||||||||||
as a % of sales |
6.2 | 6.4 | 6.5 | 7.7 | 4.4 | |||||||||||||||||||||||||||
EBIT |
312 | 657 | 1,042 | 1,852 | 175 | |||||||||||||||||||||||||||
as a % of sales |
5.3 | 5.5 | 5.7 | 6.9 | 2.9 | |||||||||||||||||||||||||||
Net income |
875 | 2,444 | 2,775 | 4,168 | 219 | |||||||||||||||||||||||||||
per common share in euros |
0.80 | 2.22 | 2.54 | 3.84 | 0.21 | |||||||||||||||||||||||||||
Net income from continuing
operations as a % of
stockholders equity (ROE) |
17.4 | 24.5 | 18.1 | 21.0 | 4.6 |
period ended 2007 | period ended 2008 | |||||||||||||||||||||||||||||||
Inventories as a % of sales |
11.7 | 12.8 | 14.2 | 12.0 | 13.9 | |||||||||||||||||||||||||||
Net debt: group equity ratio |
(9):109 | (12):112 | (7):107 | (32):132 | 4:96 | |||||||||||||||||||||||||||
Total employees (in thousands) |
124 | 126 | 128 | 124 | 134 | |||||||||||||||||||||||||||
of which discontinued
operations |
6 | 6 | 6 | 6 | 6 |
28
| Production facility will accelerate the uptake of energy-efficient lighting bulbs | |
| Production facility will fuel economic growth in Southern Africa |
| Philips will enter into a brand license agreement to transfer its North American consumer TV activities to Funai | ||
| Philips will continue to take steps to improve profitability of its TV operations by further optimizing its supply base | ||
| Charges of up to EUR 125 million will be taken during 2008 in connection with the above |
| Acquisition expands Philips presence in Chinas growing healthcare market and offers export platform to other emerging markets | ||
| Deal strengthens Philips presence in growing market for economy- and mid-range patient monitors |